XNYS · Medical Instruments & Supplies
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$234.11-0.69%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
66/100
Positive
Score components
TickerWhale View
Resmed scores 66 out of 100 overall, which we rate positive. Risk is its strongest area and Technical its weakest.
What helps
- Quality & growth
- Valuation
- Risk
What to watch
- Technical
Quality & growth
30%80Strong
- Revenue growth 9.8%
- EPS growth 9.7%
Valuation
25%59Positive
- P/E 22.3
- EV/Sales 5.9
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea, combined with aging populations and increasing prevalence of obesity, is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
#323 by market cap in our coverage · ~10,600 employees · Listed 1995-06-02 · www.resmed.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#23 / 139sector rank by TickerWhale Score
TickerWhale Score 66 vs sector average 54.6 (+11.4)
Revenue growth (industry)Top 43%
Gross margin (industry)Top 20%
Return on equity (industry)Top 7%
P/E (industry)Cheaper than 92%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
49/100Moderate vs universe
Ranks 49th of 100 covered names on our technical composite — the composite itself scores 56/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
2 buy · 3 sell · 3 neutral of 8 votes
TickerWhale rates RMD's technical setup middling — 49th percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
5 / 9constructive
- vs 200-day+4.4%
- vs 50-day+1.1%
Momentum
Mixed
- RSI (14)47 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength30· trending
- MACD (12,26,9)sell(histogram -1.814)
How the classic verdict is reached
Moving averages (9) agree on buy — 5 buy vs 4 sell — and carry one vote between them.
Oscillators (7) vote individually: 1 buy · 3 sell · 3 neutral.
Result — 2 buy vs 3 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)22.3
- P/S (TTM)6.0
- P/B5.2
- EV/EBITDA—
- EV/Sales5.9
- PEG2.31
Profitability & returns
- Gross margin61.6%
- Net margin26.9%
- ROE23.3%
- Debt/Equity0.10
Growth
- Revenue growth (YoY)9.8%
- EPS growth (YoY)9.7%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $34.0B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RMDCurrentResmed | 66 | 56 | 22.3 | — | 5.2 | 5.9 | $234.11 | -0.69% | +9.8% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.